Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Iambic Therapeutics

Iambic to Present New Pre-Clinical NSCLC Data for IAM1363, a Selective Type II Inhibitor for HER2 Cancers, at the 2025 World Conference on Lung Cancer
From Iambic Therapeutics
Via Business Wire
Iambic to Participate in September Investor Conferences
From Iambic Therapeutics
Via Business Wire
Former Amgen SVP of Global Research and Renowned Cell Biologist Ray Deshaies Named to Iambic’s Scientific Advisory Board
From Iambic Therapeutics
Via Business Wire
Iambic Named to CNBC’s 2025 Disruptor 50 List
From Iambic Therapeutics
Via Business Wire
Iambic Completes Dose Escalation in Ongoing Phase 1/1B Study of Lead Program IAM1363, a Small Molecule Inhibitor of Wild-Type and Oncogenic HER2 Mutant Proteins
From Iambic Therapeutics
Via Business Wire
Iambic Therapeutics to Participate in June Investor Conferences
From Iambic Therapeutics
Via Business Wire
Iambic Therapeutics Appoints Michael Secora, Ph.D. as Chief Corporate Development Officer and Chief Financial Officer
From Iambic Therapeutics
Via Business Wire
Iambic Therapeutics to Present at the 43rd Annual JP Morgan Healthcare Conference
From Iambic Therapeutics
Via Business Wire
Iambic Therapeutics Announces Appointment of Peter Olson, Ph.D., as Chief Scientific Officer
From Iambic Therapeutics
Via Business Wire
Iambic Therapeutics Announces “Enchant,” an AI Platform that Predicts Clinical Outcomes from the Earliest Stages of Drug Discovery
From Iambic Therapeutics
Via Business Wire
Iambic Therapeutics Named to the Endpoints 11 List of Biotech’s Most Promising Startups
From Iambic Therapeutics
Via Business Wire
Iambic Therapeutics Announces the Addition of Dr. Mary Tagliaferri to Its Board of Directors
From Iambic Therapeutics
Via Business Wire
Iambic Therapeutics Closes $50 million Series B Extension to Broaden its Pipeline of AI-Discovered Clinical Oncology Programs
From Iambic Therapeutics
Via Business Wire
Iambic Therapeutics Announces Poster Presentation for IAM1363, a Clinical Stage Type II HER2 Inhibitor, at the 2024 ASCO Annual Meeting
From Iambic Therapeutics
Via Business Wire
Iambic Therapeutics to Present New Pre-Clinical Data for IAM1363, a Selective and Brain-Penetrant Inhibitor of Both HER2 Wild-Type and Oncogenic Mutants, at the 2024 AACR Annual Meeting
From Iambic Therapeutics
Via Business Wire
Iambic Therapeutics Announces First Patient Dosed in Phase 1 Clinical Study of IAM1363, a Highly Selective HER2 Inhibitor for the Treatment of Solid Tumors
From Iambic Therapeutics
Via Business Wire
Iambic Therapeutics Announces New Research Published in Nature Machine Intelligence Demonstrating the Capabilities of Its Generative AI NeuralPLexer Technology to Predict Protein-Ligand Complex Structures
From Iambic Therapeutics
Via Business Wire
Iambic Therapeutics Expands Leadership Team With the Appointment of Neil Josephson, MD as Chief Medical Officer
From Iambic Therapeutics
Via Business Wire
Iambic Therapeutics Announces Close of Oversubscribed $100 Million Series B Financing to Advance AI-Discovered Therapeutics into Clinical Development and Enters Collaboration with NVIDIA
From Iambic Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.